Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad) [MMR-varicella zoster virus vaccine] and a booster dose of Infanrix hexa [Hib-DTaP-hepatitis B-poliovirus vaccine] in healthy children 12 to 23 months of age

X
Trial Profile

An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad) [MMR-varicella zoster virus vaccine] and a booster dose of Infanrix hexa [Hib-DTaP-hepatitis B-poliovirus vaccine] in healthy children 12 to 23 months of age

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa)
  • Indications Chickenpox; Diphtheria; Haemophilus infections; Hepatitis B; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 08 Apr 2009 Actual end date (Mar 2008) added as reported by ClinicalTrials.gov.
    • 01 Jul 2008 The expected completion date for this trial is now 1 Mar 2008, according to ClinicalTrials.gov.
    • 01 Jul 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top